Japanese Journal of Ophthalmology最新文献

{"title":"Comparison of intraocular pressure elevation following intravitreal injection of 70 µl aflibercept 8 mg.","authors":"Xien Lu, Keiko Kataoka, Mariko Kumagai, Yuta Nochi, Akiko Yamamoto, Rie Ko, Annabelle A Okada","doi":"10.1007/s10384-025-01239-7","DOIUrl":"https://doi.org/10.1007/s10384-025-01239-7","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the effect of increased injection volume on intraocular pressure (IOP) following intravitreal injections of aflibercept 8 mg (70 µl) compared to conventional anti-vascular endothelial growth factor drugs.</p><p><strong>Study design: </strong>Retrospective observational study METHODS: This retrospective observational study included eyes treated with 50 µl of either aflibercept 2 mg or faricimab 6 mg, followed by a switch to 70 µl of aflibercept 8 mg. IOP was measured before and 30 minutes after intravitreal injections. IOP changes in treated and fellow eyes were analyzed, with potential associations examined between IOP changes and clinical parameters.</p><p><strong>Results: </strong>A total of 88 eyes from 85 patients were switched to aflibercept 8 mg during the study period. Due to incomplete data, 17 eyes from 15 patients were excluded, leaving 71 eyes from 70 patients for the analysis. IOP significantly increased from 13.2 ± 2.9 mmHg to 19.1± 5.4 mmHg (P< 0.001) with 50 µl injections and from 13.3 ± 2.9 mmHg to 19.8 ± 4.8 mmHg (P<0.001) with 70 µl injections. The IOP increases were 6.0 ± 5.0 mmHg with 50 µl injections and 6.5 ± 4.3 mmHg with 70 µl injections, with no statistically significant difference (P = 0.20). An IOP exceeding 26 mmHg was observed in 6 eyes treated with 50 µl injections and 10 eyes with 70 µl injections, with no significant difference in IOP distribution between the volumes (P = 0.20).</p><p><strong>Conclusion: </strong>There was no additional increase in IOP 30 minutes after intravitreal injections when switching from 50 µl to 70 µl volumes.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144496655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of a randomised trial comparing 360° and 180° schlemm's canal incisions in suture trabeculotomy ab interno for primary open-angle glaucoma and exfoliation glaucoma: a 5-year analysis.","authors":"Tomoki Sato, Takahiro Kawaji","doi":"10.1007/s10384-025-01236-w","DOIUrl":"https://doi.org/10.1007/s10384-025-01236-w","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to report the 5-year efficacy and safety data of suture trabeculotomy ab interno (SLOT ab interno) in patients with primary open-angle glaucoma and exfoliation glaucoma.</p><p><strong>Study design: </strong>Single-centre, three-arm randomised trial.</p><p><strong>Methods: </strong>Ninety-nine eyes of 99 patients were randomly assigned to one of three groups: the 360° (n = 34), upper-180° (n = 34), and lower-180° (n = 31) groups. We evaluated intraocular pressure (IOP), medication use, and visual field progression. Surgical success (with or without medication) was defined as IOP ≤21 mmHg with a ≥20% reduction (criterion A) or IOP ≤15 mmHg with a ≥ 20% reduction (criterion B). Visual field progression was assessed by MD values at fixed postoperative time points and by the MD slope (dB/year).</p><p><strong>Results: </strong>Fifty-six of 99 eyes (56.5%) completed 5 years of follow-up. At 5 years, the mean IOP decreased from 18.8 ± 5.7 to 13.5 ± 3.1 mmHg (28% reduction, p<0.001), with medication use decreasing from 3.3 ± 1.1 to 2.0 ± 1.7 (p=0.005) and a mean MD slope of -0.2 dB/year. No significant differences in surgical success rates (criteria A and B), MD values, or MD slopes were observed among the groups.</p><p><strong>Conclusion: </strong>The extent of Schlemm's canal incisions (360°, upper-180°, or lower-180°) during SLOT ab interno has no significant effect on IOP reduction or medication use over 5 years.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reconsideration of conversion to multiple sclerosis: one-year cerebral lesion appearance rate of Japanese aquaporin-4 antibody-negative optic neuritis patients.","authors":"Satoshi Ueki, Yukari Hasegawa, Tetsuhisa Hatase, Izumi Kawachi, Takeo Fukuchi","doi":"10.1007/s10384-025-01235-x","DOIUrl":"10.1007/s10384-025-01235-x","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the rate of new cerebral lesions' appearance within 6-12 months in Japanese optic neuritis patients who at onset had no cerebral lesions suggestive of multiple sclerosis (MS) and were negative for aquaporin-4 (AQP4) antibodies.</p><p><strong>Study design: </strong>Retrospective study.</p><p><strong>Methods: </strong>Medical records of 66 adult patients with optic neuritis were reviewed. Patients positive for AQP4, myelin oligodendrocyte glycoprotein, or antinuclear antibodies were excluded. Those without cerebral lesions on initial magnetic resonance imaging (MRI) underwent follow-up MRI within 6-12 months. Clinical characteristics and subsequent neurological diagnoses were analyzed.</p><p><strong>Results: </strong>Forty-seven patients met the inclusion criteria (mean age, 41.9±16.7 years; 13 men, 34 women). Forty-two cases were unilateral, five bilateral; 19 had disc swelling, and 28 did not. The mean worst logMAR was 1.13±0.96. Two patients experienced recurrence within 1 year. Of the 27 patients without initial cerebral lesions, 20 underwent follow-up MRI; 3 (15%) developed new lesions. These three were later diagnosed as two MS and one suspected MS cases.</p><p><strong>Conclusion: </strong>Follow-up MRI within 6-12 months revealed new cerebral lesions in 15% of patients, with 10% diagnosed with MS. This highlights the importance of follow-up imaging even in AQP4 antibody-negative optic neuritis patients without initial cerebral lesions, especially in the absence of other diseases like neuromyelitis optica spectrum disorders.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scleral thickness in patients with obstructive sleep apnea syndrome.","authors":"Zeynep Akgun, Cumali Degirmenci, Sezai Tasbakan, Ozen K Basoglu, Melis Palamar","doi":"10.1007/s10384-025-01234-y","DOIUrl":"10.1007/s10384-025-01234-y","url":null,"abstract":"<p><strong>Purpose: </strong>Evaluation of scleral thickness with anterior segment optical coherence tomography (AS-OCT) in patients with obstructive sleep apnea syndrome (OSAS).</p><p><strong>Study design: </strong>Cross-sectional study.</p><p><strong>Methods: </strong>A total of 30 severe (Group 1), 30 moderate (Group 2) and 30 mild (Group 3) OSAS patients and 22 healthy volunteers (Group 4) were included in the study. Scleral thickness measurements were taken with AS-OCT, 6 mm, 4 mm and 2 mm posterior to the scleral spur, in four gaze positions. Data and findings were examined comparatively.</p><p><strong>Results: </strong>At 6 mm posterior to the scleral spur, the mean thickness was found to be significantly higher in all quadrants in Group 1 (p<0.05 for all). Superior thickness was higher in Group 2 compared to Group 4 (p=0.034). At 4 mm posterior to the scleral spur; in Group 1, the mean thickness was found higher than Group 2 and 3 only in the inferior (p=0.01, p=0.021, respectively) and was found higher than Group 4 in the nasal and inferior (p<0.001, p=0.006, respectively). At 2 mm posterior to the scleral spur; significant difference was observed between Groups 1 and 2 only in the inferior (p=0.002), between Groups 1 and 3 in the nasal and inferior (p=0.029, p=0.002), and between Groups 1 and 4 the in nasal and inferior (p=0.002, p<0.001).</p><p><strong>Conclusion: </strong>The scleral thickness measured from 6 mm posterior to the scleral spur was higher in all quadrants in patients with severe OSAS. It is possible that the increase in scleral thickness, especially in severe OSAS, is due to extracellular matrix accumulation in the scleral tissue.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144336582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a reliability criterion for the binocular Esterman visual field test.","authors":"Kazunori Hirasawa, Akari Nagayama-Ito, Chiho Maruta-Akaishizawa, Nobuyuki Shoji","doi":"10.1007/s10384-025-01238-8","DOIUrl":"10.1007/s10384-025-01238-8","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the repeatability of the binocular Esterman visual field (bEVF) test and develop a corresponding reliability criterion based on repeatability-associated factors.</p><p><strong>Study design: </strong>Prospective cross-sectional study.</p><p><strong>Methods: </strong>Ninety-five glaucoma patients underwent two bEVF tests on the same day using a Humphrey field analyzer. The repeatability of the bEVF was assessed by the agreement rate for seen and unseen points over all test points between the first and second tests. Factors associated with the repeatability were analyzed with multivariate linear regression analysis. Receiver operating characteristic (ROC) curve analysis was performed for those associated factors to identify the reliability criterion.</p><p><strong>Results: </strong>The mean agreement rate was 88.9% (95% confidence interval [CI]: 73.9%, 99.2%). A total of 44 patients (46.3%), 75 patients (78.9%), and 88 patients (92.6%) had agreement rates of more than 90%, 85%, and 80%, respectively. The false positive (FP) response rate of the bEVF test was negatively associated with the agreement rate (p<0.01). The best cutoff value according to the maximum Youden index for the FP response rate of the bEVF test was >7.1% (sensitivity = 71.0% and specificity = 88.0%), while the cutoff value based on a fixed 95% specificity was >12.1% (sensitivity = 28.6%).</p><p><strong>Conclusion: </strong>An approximately 90% agreement rate existed for the bEVF test when applied to glaucoma patients. The FP response rate was associated with the repeatability of the bEVF test, and 8% or at least 13% may serve as a useful reference to ensure an agreement rate of 80% or higher.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between acceleration of axial elongation and ocular biometry in schoolchildren.","authors":"Takehiro Yamashita, Hiroto Terasaki, Takuto Hamada, Ryo Asaoka, Naoya Yoshihara, Naoko Kakiuchi, Taiji Sakamoto","doi":"10.1007/s10384-025-01227-x","DOIUrl":"https://doi.org/10.1007/s10384-025-01227-x","url":null,"abstract":"<p><strong>Purpose: </strong>The speed of axial elongation typically slows during the growth phase; however, in some eyes, it accelerates, leading to myopia progression during school age. This study examined the association between ocular biometrics and the acceleration of axial elongation (AAE) in children.</p><p><strong>Study design: </strong>Longitudinal, prospective, observational study METHODS: This cohort study included 67 right eyes of elementary school children, tracked over six years (from ages 8.5 to 14.5). Annual measurements were conducted for optical axial length, anterior chamber depth, and lens thickness. Yearly axial elongation was calculated for each time period, and AAE was estimated using regression analysis coefficients. Spearman's correlation was used to evaluate the association between AAE and ocular biometric parameters measured in the first year.</p><p><strong>Results: </strong>The average axial length in the initial year was 23.37 ± 0.89 mm. By the sixth year, the mean axial elongation reached 1.50 ± 0.49 mm, while the average AAE was recorded as -0.015 ± 0.048. AAE was significantly correlated with first-year axial length (r = - 0.40, p < 0.001), anterior chamber depth (r = 0.33, p = 0.007), and lens thickness (r = - 0.42, p < 0.001).</p><p><strong>Conclusion: </strong>Some eyes with hyperopic ocular biometry at 8.5 years of age exhibited accelerated axial elongation during school age. Future research on myopia should consider both acceleration and axial elongation.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction in choroidal thickness associated with the progression of pachychoroid spectrum diseases.","authors":"Hidetaka Matsumoto, Junki Hoshino, Kosuke Nakamura, Yosuke Asatori, Shoji Kishi, Hideo Akiyama","doi":"10.1007/s10384-025-01230-2","DOIUrl":"https://doi.org/10.1007/s10384-025-01230-2","url":null,"abstract":"<p><strong>Purpose: </strong>Pachychoroid spectrum diseases reportedly progress from central serous chorioretinopathy (CSC) to pachychoroid neovasculopathy (PNV) and polypoidal choroidal vasculopathy (PCV). We investigated and compared choroidal thicknesses in the macular and peripheral areas among eyes with CSC, PNV, and PCV, as well as in normal control eyes.</p><p><strong>Study design: </strong>Retrospective case-control study.</p><p><strong>Methods: </strong>We studied 117 consecutive eyes with treatment-naïve pachychoroid spectrum diseases, comprising 52 eyes with CSC, 27 with PNV, and 38 with PCV, along with 106 age-, gender-, and axial length-matched normal control eyes. Widefield choroidal thickness maps generated by widefield optical coherence tomography were quantitatively analyzed. Mean choroidal thickness values in the macular, superotemporal, inferotemporal, superonasal, and inferonasal areas were determined, and then compared among the three pachychoroid spectrum diseases, and also assessed in normal controls.</p><p><strong>Results: </strong>The mean choroidal thickness reduction with aging was greater in eyes with pachychoroid spectrum diseases than in normal controls across all measured areas. Patient age increased in the order of CSC, PNV, and PCV, whereas there was no significant difference between PNV and PCV (P<0.01, CSC vs. PNV, CSC vs. PCV). Mean choroidal thickness exhibited a progressive decrease from CSC to PNV and PCV across all areas, although there were no significant differences between PNV and PCV (P<0.01, CSC vs. PCV, CSC vs. PNV).</p><p><strong>Conclusions: </strong>Overall choroidal thickness appears to decrease during the progression of pachychoroid spectrum diseases. This decline might be attributable to reduced choroidal blood flow due to the choriocapillaris attenuation associated with aging and pachychoroid pathophysiology.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of switching from existing anti-vascular endothelial growth factor drugs to ranibizumab biosimilar in neovascular age-related macular degeneration.","authors":"Hikaru Ota, Jun Takeuchi, Ryo Nonogaki, Kazuma Tamura, Hiroki Kaneko, Koji M Nishiguchi","doi":"10.1007/s10384-025-01224-0","DOIUrl":"https://doi.org/10.1007/s10384-025-01224-0","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated the clinical outcomes and aqueous humor cytokine levels in eyes with neovascular age-related macular degeneration (nAMD) switched from intravitreal aflibercept to ranibizumab biosimilar (BS).</p><p><strong>Study design: </strong>Prospective observational study.</p><p><strong>Methods: </strong>Thirty-eight eyes of 38 patients with nAMD who received aflibercept under a treat-and-extend (TAE) regimen were prospectively switched to ranibizumab BS. Eight eyes with cataracts undergoing surgery served as controls for aqueous humor cytokine analysis. Best-corrected visual acuity (BCVA) and anatomical outcomes were assessed over one year. The aqueous humor levels of vascular endothelial growth factor (VEGF)-A, angiopoietin-2 (Ang-2), and placental growth factor (PlGF) were measured before and after switching in eyes with nAMD and at surgery in controls.</p><p><strong>Results: </strong>Disease activity remained controlled in 94.3% of patients with nAMD for over one year. No significant changes were observed in the BCVA (P=0.65) after one year. Ang-2 levels remained unchanged (P=0.66) and were not significantly different between eyes with nAMD and controls both before (P=0.64) and after switching (P=0.30). PlGF levels also remained stable (P=0.12) but were significantly higher in eyes with nAMD than in controls both before (P<0.01) and after switching (P=0.03). VEGF-A levels significantly increased after switching (P<0.01) but remained lower than in the controls both before (P<0.01) and after switching (P=0.02).</p><p><strong>Conclusion: </strong>Switching from aflibercept to ranibizumab BS effectively maintained disease stability and cytokine balance in eyes with nAMD. These findings support ranibizumab BS as a viable and cost-effective alternative for long-term treatment.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six-year findings of polypoidal choroidal vasculopathy in the EVEREST II study: Japanese subgroup analysis.","authors":"Yasuo Yanagi, Ryusaburo Mori, Kelvin Yi Chong Teo, Kyu-Hyung Park, Nor Fariza Ngah, Shih-Jen Chen, Paisan Ruamviboonsuk, Nagako Kondo, Won Ki Lee, Rajesh Rajagopalan, Ryo Obata, Ian Y H Wong, Caroline Chee, Hiroko Terasaki, Tetsuju Sekiryu, Shih-Chou Chen, Timothy Y Y Lai, Gemmy Cheung, Shigeru Honda","doi":"10.1007/s10384-025-01228-w","DOIUrl":"https://doi.org/10.1007/s10384-025-01228-w","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate long-term outcomes for polypoidal choroidal vasculopathy (PCV) in Japanese patients in the EVEREST II study.</p><p><strong>Study design: </strong>A multicenter, cross-sectional study of the long-term outcomes of a cohort of patients originally treated with ranibizumab alone (monotherapy group) or in combination with photodynamic therapy PDT (combination group) in the EVEREST II study (ClinicalTrials.gov identifier, NCT01846273).</p><p><strong>Methods: </strong>Ninety participants from the six-year EVEREST II follow-up: 20 Japanese and 70 non-Japanese were included. Long-term changes in best-corrected visual acuity (BCVA) and central subfield thickness (CST) were reported in the Japanese compared to non-Japanese participants. Number of injections, types of anti-vascular endothelial growth factor (VEGF) agents used, and cases with equal visits and injections, indicating fixed dosing or treat-and-extend (TAE) administration were investigated. Outcomes were also compared between those who had verteporfin PDT during the six-year period (n=14) and those who did not (n=6).</p><p><strong>Results: </strong>The Japanese and non-Japanese participants had similar baseline characteristics. The mean age for Japanese participants was 76±4.47 years, with 25% being women. BCVA improved from baseline to year 2 in both groups (P < 0.05). At six years, BCVA was maintained in the Japanese (67.2 ETDRS letters) but decreased in the non-Japanese participants (from 68.8 to 53.5 letters). The Japanese participants received more injections than the non-Japanese (12.5 vs. 7.57, P=0.017). Aflibercept was the most frequently used anti-VEGF agent, and the number of fixed dosing or TAE administration was higher in the Japanese participants. No significant differences were found in functional and anatomical outcomes between those who received PDT and those who did not (all P > 0.05). However, non-PDT participants had numerically worse BCVA at the final visit.</p><p><strong>Conclusions: </strong>This study highlights positive long-term outcomes for Japanese PCV patients and underscores the need for further research to validate these findings in broader patient populations.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors determining timing of first recurrence after three loading aflibercept injections in newly diagnosed neovascular age-related macular degeneration.","authors":"Sang Hyeok Lee, Mee Yon Lee","doi":"10.1007/s10384-025-01225-z","DOIUrl":"https://doi.org/10.1007/s10384-025-01225-z","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate factors affecting timing of the first recurrence after three loading aflibercept injections in patients with newly diagnosed neovascular age-related macular degeneration (NAMD).</p><p><strong>Study design: </strong>Retrospective chart review.</p><p><strong>Methods: </strong>A retrospective study was conducted on 193 eyes from 193 patients newly diagnosed with NAMD who received monthly three loading aflibercept injections and a fourth injection by pro-re-nata therapy regimen for recurrence between January 2016 and May 2023. Recurrence was defined as reaccumulation of subretinal or intraretinal fluid or new or increased retinal or subretinal hemorrhage. Patients were divided into two groups. One group received a fourth injection within 12 weeks after the third dose of aflibercept (Group A) and the other group received a fourth injection after 12 weeks (Group B).</p><p><strong>Results: </strong>In group A (65 eyes) compared to group B (128 eyes), the frequency of polypoidal choroidal vasculopathy (PCV) was higher (60.0%: 36.7%), the frequency of retinal angiomatous proliferation was lower (6.2%: 18.0%), and the optical coherence tomography (OCT) findings showed that pigment epithelial detachment (PED) of hollow type was more likely to be observed compared to solid type (OR=3.14, p=0.013) or mixed type (OR=3.67, p=0.003) of PED; sharply peaked PED was more common (OR=2.05, p=0.045) and less likely to be seen in females (OR=0.46, p=0.034).</p><p><strong>Conclusion: </strong>In patients with newly diagnosed NAMD who received three injection loading doses of aflibercept, earlier recurrence was predicted when PCV was present, when a hollow type of PED was observed on OCT, and when the patient was a man.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}